Tackling the Last Mile: A major component to successfully establish radioligand therapy

Kelsey L. Pomykala, Marcus Würker and Ken Herrmann Journal of Nuclear Medicine December 2022, jnumed.122.264900; DOI: https://doi.org/10.2967/jnumed.122.264900 With two promising radioligand therapies recently approved by the Food & Drugs Administration (FDA) - Lutathera (¹⁷⁷Lu-Dotatate) and Pluvicto (¹⁷⁷Lu-PSMA-617) - the stage is set for a radioligand therapy renaissance. The first difficult 25 miles of the marathon have been run . The last mile is to successfully delivery the therapy to patient. >> Read the article